ERBB2 and breast cancer: Moreover, a clinical trial for early-stage HER2-positive BC observed that tumors with heterogeneous HER2 expression showed no complete response to HER2-targeted therapy with trastuzumab emtansine and pertuzumab, whereas tumors with homogeneous HER2 expression achieved a 55% complete response rate [20].